Berger Financial Group Inc decreased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,871 shares of the company’s stock after selling 247 shares during the quarter. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $2,296,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in JNJ. Moneta Group Investment Advisors LLC lifted its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson in the 4th quarter worth approximately $4,609,399,000. Providence Capital Advisors LLC lifted its holdings in Johnson & Johnson by 141,974.0% in the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after purchasing an additional 4,747,612 shares during the last quarter. Morgan Stanley lifted its holdings in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Johnson & Johnson by 61.0% in the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after purchasing an additional 4,278,512 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on JNJ. Barclays boosted their target price on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Morgan Stanley cut their price target on Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. Royal Bank of Canada began coverage on Johnson & Johnson in a report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price target for the company. Finally, Raymond James cut their price target on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $169.19.
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $149.91 on Tuesday. The business’s fifty day moving average price is $154.52 and its two-hundred day moving average price is $160.29. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04. The stock has a market capitalization of $360.88 billion, a price-to-earnings ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. The firm had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. As a group, analysts predict that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s payout ratio is presently 35.34%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- The How And Why of Investing in Oil Stocks
- Safeguard your portfolio with these three bargain stocks
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Membership clubs gain leverage for the consumer rebound
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.